Shanghai Henlius Biotech (SEHK:2696) Reports Strong Half Year Growth, Is It Overvalued?

Shanghai Henlius Biotech (SEHK:2696) drew fresh attention after reporting half year 2026 sales of CNY 3,588.23 million and net income of CNY 430.44 million, alongside a new Hong Kong principal business address.

Shanghai Henlius Biotech’s recent half year update has come alongside a strong shift in market sentiment, with a 22.55% 1 month share price return and a 16.38% year to date share price return, even though the 1 year total shareholder return declined 11.43%.

Spot fresh momentum in Shanghai Henlius Biotech, and then widen your watchlist with hand picked 617 high quality undiscovered gems that may be flying under most investors’ radar.

Shanghai Henlius Biotech now sits between two stories. One is improving half year earnings and a solid recent share price move. The other is a longer term return that still lags. How does that balance show up in the current valuation?

Price-to-Earnings of 36.7x: Is it justified?

Shanghai Henlius Biotech now trades on a P/E of 36.7x, which places the HK$68.2 share price at a premium compared to both peers and an estimated fair level.

The P/E ratio compares the current share price with the company’s earnings per share. For a biopharma group like Shanghai Henlius Biotech, a higher P/E often reflects expectations that earnings can continue to build from a pipeline of approved products and late stage candidates.

In this case, the current P/E of 36.7x is well above the Hong Kong biotechs industry average of 19.6x and above the peer group average of 27.7x. It is also higher than the estimated fair P/E of 21.3x that the SWS fair ratio suggests is more in line with fundamentals. This points to a level the market could move towards if sentiment cools or growth expectations change.

For investors who want to go deeper into how that fair ratio is calculated and what would need to change for it to close, Explore the SWS fair ratio for Shanghai Henlius Biotech.

Result: Preferred multiple of price-to-earnings of 36.7x (OVERVALUED)

However, Shanghai Henlius Biotech still faces risks if current earnings momentum slows, or if sentiment shifts away from higher P/E biotech stocks.

Find out about the key risks to this Shanghai Henlius Biotech narrative.

Another view on Shanghai Henlius Biotech’s valuation

While the P/E of 36.7x suggests Shanghai Henlius Biotech is expensive relative to peers and the fair ratio of 21.3x, the SWS DCF model points the other way. On that measure, the HK$68.2 share price sits well below an estimated fair value of HK$208.59, which casts the current premium multiple in a very different light. Which signal do you treat as more important?

For readers who want to see how this cash flow view is built and what assumptions drive the gap, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shanghai Henlius Biotech for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 257 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Shanghai Henlius Biotech now pulled between premium valuation signals and a discounted DCF view, this is a moment to check the data yourself and move quickly to shape your own opinion. A simple way to round out that view is to weigh up the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Shanghai Henlius Biotech?

If Shanghai Henlius Biotech has your attention, do not stop there. Use the time you have today to line up a few more high quality prospects.

• Expand your opportunity set by reviewing a 257 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them.
• Strengthen your income side by scanning a 413 dividend fortresses that focus on established payouts with higher yields.
• Protect your downside by working through a 298 resilient stocks with low risk scores that aim to balance return potential with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com